Matthew Robson is a patent litigation partner in the New York Office. Mr. Robson has litigated cases involving a wide array of technologies, with extensive experience in life science, medical device, semiconductor, and data analytics / AI matters.
The American Lawyer has recognized Mr. Robson as a "Litigator of the Week" for his work securing a pivotal CRISPR genome-engineering victory for the Broad Institute. Mr. Robson’s victories in the CRISPR space have been widely covered in the press, including by Reuters, the Wall Street Journal, Science, and Nature.
Lawdragon has named Mr. Robson as one of the top 500 Leading Global IP Lawyers, and the LMG Life Sciences Awards twice selected Mr. Robson’s cases as Patent Impact Case of the Year. Law360 has recognized Mr. Robson as a "Rising Star" in Life Sciences patent litigation.
Mr. Robson has extensive experience representing both plaintiffs and defendants in all aspects of case preparation, discovery, trial, and appeal. He has litigated in jurisdictions throughout the country, including the Northern District of Illinois, District of Delaware, Northern and Central Districts of California, Eastern and Western Districts of Texas, and before the International Trade Commission.
- American Express
- AngioScore
- Broad Institute of Harvard and MIT
- Champion Laboratories
- C.R. Bard
- Cree
- Dow Chemical
- Merck Sharp & Dohme
- Motorola
- Samsung
- Samsung Bioepis
- Representing a major semiconductor company in a patent infringement action targeting its RF communications chips.
- Representing a major smartphone company in a patent infringement action targeting its wireless communications (4G, 5G, WiFi, Bluetooth) products.
- Secured victory for the Broad Institute in its long-running CRISPR-Cas9 patent dispute with the University of California, University of Vienna, and Emmanuelle Charpentier. On March 27, 2026, the PTAB ruled on remand from the Federal Circuit that Broad’s inventor was the first to conceive of the use of CRISPR-Cas9 in eukaryotic cells, again confirming Broad's entitlement to foundational CRISPR patents. The ruling was widely covered in the press, including by Reuters ("Nobel Prize Winners Face New Loss in Bid for US CRISPR Patents") and Law360 ("Nobel Prize Winners Again Lose Patent Fight Over CRISPR") (March 2026).
- Obtained a preliminary and then permanent injunction for medical device client BlephEx, completely prohibiting its competitor from selling its device in the US.
- Secured a pivotal patent ruling for the Broad Institute, with the PTAB confirming Broad's entitlement to foundational CRISPR-Cas9 patents. Mr. Robson was recognized as a "Litigator of the Week" by The American Lawyer for this victory, which was widely covered in the press, including by the Wall Street Journal ("CRISPR Patent Ruling Picks Winners in Dispute Over Gene-Editing Technology") and Reuters ("Breakthrough Gene-Editing Technology Belongs to Harvard, MIT") (Feb 2022).
- Represented the Broad Institute in an appeal of an earlier CRISPR patent interference, obtaining a victory for Broad.
- Represented American Express subsidiary InAuth, Inc. in patent infringement litigation brought against its authentication technologies, obtaining a complete dismissal of all infringement claims with prejudice (C.D. Cal.).
- Represented American Express in patent infringement litigation brought against its prepaid card products, obtaining summary judgment of both non-infringement and invalidity (W.D. Wis.).
- Represented American Express Co. in patent infringement litigation brought against its Travelers Cheque™ Card products, obtaining summary judgment of non-infringement and a Federal Circuit affirmance.
- Represented AngioScore, a wholly owned subsidiary of Spectranetics, in patent inventorship litigation brought against three issued AngioScore medical device patents, obtaining a dismissal of all claims, with prejudice (N.D. Cal.).
- Represented Cree Inc. in a Section 337 Investigation related to light-emitting diodes and related products. The ALJ found a violation in favor of Cree and ordered sanctions against the opposing side for discovery abuse. The case settled favorably prior to a final Commission determination.
- Represented Motorola in a multi-patent suit against Apple in the Northern District of Illinois before the Honorable Richard Posner, sitting by designation, obtaining dismissal of all claims on summary judgment.
- Represented a major smartphone maker in a Section 337 investigation brought by Microsoft, obtaining an order of "no violation" as to eight of nine patents. The remaining patent was designed around.
- Represented the CEO of a major pharmaceutical company in a securities class action lawsuit, which settled on favorable terms.
- Harvard Law School
(J.D., cum laude, 2007)- Harvard Law Review:
- Editor
- Harvard Law Review:
- The Cooper Union for the Advancement of Science and Art
(B.E., summa cum laude, Mechanical Engineering, 2004)
- The State Bar of New York
- United States Court of Appeals:
- Federal Circuit
- First Circuit
- United States District Court
- Southern District of New York
- Eastern District of Michigan
- Law Clerk to the Hon. Bruce M. Selya:
- United States Court of Appeals for the First Circuit, 2009-2010
- United States Court of Appeals for the First Circuit, 2009-2010
- Cravath, Swaine & Moore LLP:
- Associate, 2007-2009
- Named by Lawdragon 500 Leading Global IP Lawyers, Patent Litigation, ITC, Portfolio License (2025)
- Named “Litigator of the Week” by The American Lawyer Litigation Daily (2022)
- Named a “Rising Star” in Life Sciences by Law360 (2019)
- LMG Life Sciences Awards - Patent Impact Cases of the Year (2019)
- The Supreme Court, 2005 Term—Leading Cases, 120 HARV. L. REV. 332 (2006).
- Recent Case, First Circuit Defines an Efficient Market for Fraud-on-the-Market Purposes—In re PolyMedica Corp. Securities Litigation, 119 HARV. L. REV. 2284 (2006).
Loading...